Bristol Myers Squibb Receives Positive CHMP
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM) Bristol Myers Squibb (NYSE: BMY) today announced that the Committee…
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing…
Boehringer Ingelheim inaugurates the largest European development center for biotechnology
Boehringer Ingelheim inaugurates the largest European development center for biotechnology Boehringer Ingelheim today inaugurated its state-of-the-art Biologicals Development Center (BDC) in Biberach an der Riß, Germany. The new high-tech facility…
Lilly to Divest BAQSIMI to Amphastar
Lilly to Divest BAQSIMI to Amphastar In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) have entered into a definitive agreement…
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA Daiichi Sankyo (TSE: 4568) today announced thatthe U.S. Food and Drug Administration (FDA) has extended the…
AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS
AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 27, 2023, after the close of the U.S. financial…
AbbVie Announces Late-Breaking Results
AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting…
A backpack full of multiple sclerosis therapy
Multiple sclerosis (MS) is a devastating autoimmune disease that destroys the protective myelin covering around nerves, disrupting communication between the brain and body, and causing patients’ ability to move and…
Cocktail of modified antibodies provides strong effect against SARS-CoV-2
Cocktail of modified antibodies provides strong effect against SARS-CoV-2 Is it possible to improve the antibodies that the body produces to fight SARS-CoV2? In a study led by researchers from…
Clinical trial begins using CAR T cells to potentially cure HIV
UC Davis Health researchers have dosed the second participant in their clinical trial looking to identify a potential cure for HIV utilizing CAR T-cell therapy. The novel study uses immunotherapy.…
Anti-obesity medications could be sold for lower prices
New research shows that several anti-obesity medications could be manufactured and profitability sold worldwide at far lower estimated lower prices compared to their high costs, according to a new study…
T-cell vaccine for COVID-19 may last longer than current vaccines
The current COVID-19 vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time.…